Hyperkalemia Completed Phase 3 Trials for Sodium zirconium cyclosilicate (DB14048)

Also known as: Hyperkalemia (HK) / Hyperkalaemia / Hyperpotassaemia / Hyperpotassemia / Potassium overload / Potassium [K] excess

IndicationStatusPhase
DBCOND0003949 (Hyperkalemia)Completed3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03172702Open-label Safety of Sodium Zirconium Cyclosilicate for up to 12 Months in Japanese Subjects With HyperkalemiaSupportive Care
NCT03303521A Study to Test Whether ZS (Sodium Zirconium Cyclosilicate) Can Reduce the Incidence of Increased Blood Potassium Levels Among Dialized Patients.Treatment
NCT02088073Safety & Efficacy of Zirconium Silicate Dosed for 28 Days in Hyperkalemia.Supportive Care
NCT02107092Open-label Safety & Efficacy of ZS (Sodium Zirconium Cyclosilicate)10g qd to Extend Study ZS-004 in Hyperkalemia.Supportive Care
NCT02163499Open-label Safety and Efficacy of Sodium Zirconium Cyclosilicate for up to 12 MonthsSupportive Care
NCT02875834A Study to Investigate the Safety and Efficacy of ZS in Patients With HyperkalemiaTreatment